Brief: Oasmia Signs Manufacturing Agreement With Lonza For Ovarian Cancer Drug Candidate Cantrixil

Vivesto AB

21/03/2022 08:07

March 21 (Reuters) - Oasmia Pharmaceutical AB  OASM.ST :
    * OASMIA SIGNS MANUFACTURING AGREEMENT WITH LONZA FOR
OVARIAN
CANCER DRUG CANDIDATE CANTRIXIL
    * UNDER AGREEMENT, LONZA WILL DELIVER CGMP-STANDARD DRUG
SUBSTANCE
FOR CLINICAL SUPPLY
    * MANUFACTURING TO BEGIN LATER IN MARCH 2022 AT LONZA'S
HPAPI
MANUFACTURING LABORATORIES IN NANSHA, CHINA
    * COLLABORATION IS PROJECTED TO TAKE CANTRIXIL THROUGH
PLANNED
PHASE II CLINICAL TRIAL
    * MANUFACTURING IS EXPECTED TO BEGIN LATER IN MARCH 2022

Source text for Eikon:  ID:nMFNc2563m 
Further company coverage:  OASM.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))